Cardiology Pharmacy Specialist @IU_Health | PGY1/PGY2 cardiology @OSUWexMed | @Waynestatepharm | Tweets are my own opinion |
Joined May 2019
- Tweets316
- Following99
- Followers315
- Likes265
A surrogate outcome does not mean a new age. This type of study leads to over prescribing based on a soft endpoint with financial detriment to the patient with no proven benefit in hard outcomes. Does the next drug that reduces BNP create a new age for heart failure?
🔥 #CONFIDENCE in @NEJM
Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D
A new age of combination therapies has arrived in #CKM care #ERA25
nejm.org/doi/full/10.1056/NE…
So that statistically significant ~1.5% reduction of a composite endpoint driven by the weakest of the endpoints in COLCOT was actually just noise? Who would have thought? #colchicine
acc.org/Latest-in-Cardiology…
Ryan Caputo, PharmD, BCCP retweeted
🚨When it is a YES ✅ and not 🚫in DOACS 💊
👉🏻 J Am Coll Cardiol 2024;83:444-465.
Ryan Caputo, PharmD, BCCP retweeted
New: Either ACEi or ARB therapy protect against kidney failure in those with advanced CKD. Neither therapy provided a death benefit for those with late-stage CKD: ecs.page.link/SWNAD
Ryan Caputo, PharmD, BCCP retweeted
Hence my Antibiotic Stewardship for the 21st Century Lecture: slides
Analogous to LVAD ramp studies, a trial assessing RHC to guide optimal pacing rates for HFpEF may allow for further individualization of pacer settings beyond the algorithm used in MyPace
jamanetwork.com/journals/jam…
If there was half as much enthusiasm about initiating spironolactone as there is about sacubitril/valsartan, the world would be a better place 😌
Ryan Caputo, PharmD, BCCP retweeted
Clinical strategies for mitigating adverse events with GLP-1 medicines @BevTchangMD #ADA2024 pubmed.ncbi.nlm.nih.gov/3477…
Patient with ACS found to have new AF.
Something commonly overlooked is in Pioneer AF-PCI, rivaroxaban was reduced to 15 mg daily in pts otherwise indicated for 20 mg daily.
Make things simple and use apixaban which was studied at the same dose as used in its landmark AF trial.
Ryan Caputo, PharmD, BCCP retweeted
When to suspect cardiac amyloidosis?
Echo features:
🔹Nondilated LV with thickened walls
🔹E/A > 2 and E/e’ > 14
🔹Biatrial enlargement
🔹Valvular thickening
🔹Apical sparing strain pattern
…and the following clinical features, 🖼️ via British Society of Echocardiography:
A scientific statement on CYP2C19 testing to guide anti platelet therapy that I have to respectfully disagree with.
A 🧵 on why genomic testing a misguided solution to a complicated problem
ahajournals.org/doi/abs/10.1…
6) Stent technology has vastly improved each decade and uptake of intravascular imaging has reduced procedural factors that contribute to stent thrombosis. As PCI continues to advance, the benefits of more potent antiplatelet therapy has and will continue to diminish IMHO.
It never made sense that HM3 patients who almost certainly develop acquired von Willebrand syndrome would need an antiplatelet agent and we finally have the data proving it!
📢 A NEW #ISHLTConsensusStatement on Strategies to Prevent and Manage #Hemocompatibility Related Adverse Events in Patients with Durable #VADs is now available online at bit.ly/hemoconsensus.
Check out the top takeaways from this document below. ⏬🫀💡 #HF #TxPharm #LVAD
